Exelixis Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 5.12
Dividend & YieldN/A$ (N/A)
Beta 0.69
Market capitalization 5.3B
Operating cash flow 385.37M
ESG Scores unknown

Company description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 17.41M 30.39M 49.46M 66.1M
Total Cashflows From Investing Activities -297.85M -587.25M -131.22M -42.88M
Net Borrowings
Total Cash From Financing Activities 9.69M 12.55M -25.13M -14.8M
Change To Operating Activities -8.53M -1.29M -25.23M 30.42M
Issuance Of Stock 17.28M 22.5M 24.89M 24.31M
Net Income 690.07M 321.01M 111.78M 231.06M
Change In Cash 127.56M -47.74M 52.63M 343.12M
Effect Of Exchange Rate
Total Cash From Operating Activities 415.72M 526.96M 208.98M 400.8M
Depreciation 7.77M 8.35M 9.14M 13.63M
Change To Account Receivables -85.47M 43.72M -42.47M -122.32M
Other Cashflows From Financing Activities -13k -42k
Change To Netincome -202.36M 130.51M 128.2M 195.12M
Capital Expenditures -33.3M -12.83M -30.34M -64.22M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 182.26M 336.96M 547.85M 693.72M
Income Before Tax 452.09M 398.11M 130.84M 294.15M
Net Income 690.07M 321.01M 111.78M 231.06M
Selling General Administrative 206.37M 228.24M 293.36M 401.71M
Gross Profit 828.58M 934.68M 951.27M 1.38B
Ebit 439.95M 369.47M 110.06M 286.67M
Operating Income 439.95M 369.47M 110.06M 286.67M
Interest Expense
Income Tax Expense -237.98M 77.1M 19.06M 63.09M
Total Revenue 853.83M 967.77M 987.54M 1.43B
Cost Of Revenue 25.25M 33.1M 36.27M 52.87M
Total Other Income ExpenseNet 12.14M 28.64M 20.78M 7.49M
Net Income From Continuing Ops 690.07M 321.01M 111.78M 231.06M
Net Income Applicable To Common Shares 690.07M 321.01M 111.78M 231.06M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 134.83M 199.7M 258.22M 405.62M
Total Stockholder Equity 1.29B 1.69B 1.88B 2.21B
Other Current Liabilities 19.09M 21.72M 41.42M 48.23M
Total Assets 1.42B 1.89B 2.14B 2.62B
Common Stock 300k 305k 312k 319k
Other Current Assets 9.8M
Retained Earnings -880.36M -559.35M -447.57M -216.51M
Treasury Stock -701k 3.07M 4.48M -758k
Cash 314.77M 266.5M 319.22M 647.17M
Total Current Liabilities 105.47M 142.75M 204.66M 337.59M
Other Stockholder Equity -701k 3.07M 4.48M -758k
Property, Plant, and Equipment 56.76M 90.73M 110.39M 149.15M
Total Current Assets 897.02M 1.01B 1.45B 1.83B
Net Tangible Assets 1.22B 1.62B 1.82B 2.15B
Net Receivables 162.77M 126.33M 165.38M 285.55M
Accounts Payable 10.9M 11.58M 23.63M 24.26M


Insider Transactions

Here are the insider transactions of stock shares related to Exelixis Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HALEY PATRICK JOSEPHSale at price 17.94 per share.D2022-09-12Officer40k
HALEY PATRICK JOSEPHConversion of Exercise of derivative security at price 6.21 per share.D2022-09-12Officer40k
SENNER CHRISTOPHER J.Conversion of Exercise of derivative security at price 6.21 per share.D2022-08-11Chief Financial Officer225k
MORRISSEY MICHAEL MStock Award(Grant) at price 0.00 per share.D2022-08-03Chief Executive Officer94k
LAMB PETERStock Award(Grant) at price 0.00 per share.D2022-08-03Officer28.95k
HESSEKIEL JEFFREY JStock Award(Grant) at price 0.00 per share.D2022-08-03General Counsel28.95k
SENNER CHRISTOPHER J.Stock Award(Grant) at price 0.00 per share.D2022-08-03Chief Financial Officer32.57k
HALEY PATRICK JOSEPHStock Award(Grant) at price 0.00 per share.D2022-08-03Officer28.95k
HALEY PATRICK JOSEPHSale at price 18.21 per share.D2022-05-27Officer18.81k
WYSZOMIERSKI JACK LStock Award(Grant) at price 0.00 per share.D2022-05-26Director19.57k
PAPADOPOULOS STELIOS BStock Award(Grant) at price 0.00 per share.D2022-05-26Director19.57k
POSTE GEORGE HStock Award(Grant) at price 0.00 per share.D2022-05-26Director19.57k
MARCHESI VINCENT TStock Award(Grant) at price 0.00 per share.D2022-05-26Director19.57k
FELDBAUM CARL B. ESQStock Award(Grant) at price 0.00 per share.D2022-05-26Director10.18k
FREIRE MARIA CStock Award(Grant) at price 0.00 per share.D2022-05-26Director19.57k
WRIGHT JACQUELINEStock Award(Grant) at price 0.00 per share.D2022-05-26Director10.18k
HESSEKIEL JEFFREY JSale at price 20.07 - 25.39 per share.D2022-05-16General Counsel36k
WILLSEY LANCESale at price 19.65 per share.D2022-05-12Director40k
WILLSEY LANCEConversion of Exercise of derivative security at price 3.13 per share.D2022-05-12Director40k
WYSZOMIERSKI JACK LSale at price 23.00 per share.D2022-04-04Director6.7k
WYSZOMIERSKI JACK LConversion of Exercise of derivative security at price 3.13 per share.D2022-04-04Director40k
HALEY PATRICK JOSEPHSale at price 22.43 - 23.00 per share.D2022-04-01Officer20k
HALEY PATRICK JOSEPHConversion of Exercise of derivative security at price 6.21 per share.D2022-04-01Officer20k
HESSEKIEL JEFFREY JSale at price 22.00 per share.D2022-03-29General Counsel18k
MORRISSEY MICHAEL MStock Award(Grant) at price 0.00 per share.D2022-03-04Chief Executive Officer270.42k
LAMB PETERStock Award(Grant) at price 0.00 per share.D2022-03-04Officer59.49k
HESSEKIEL JEFFREY JStock Award(Grant) at price 0.00 per share.D2022-03-04General Counsel67.88k
SENNER CHRISTOPHER J.Stock Award(Grant) at price 0.00 per share.D2022-03-04Chief Financial Officer75.98k
HALEY PATRICK JOSEPHStock Award(Grant) at price 0.00 per share.D2022-03-04Officer70.72k
MORRISSEY MICHAEL MStock Gift at price 0.00 per share.I2022-03-02Chief Executive Officer50k
GARBER ALAN MSale at price 21.00 per share.D2022-03-01Director21.3k
GARBER ALAN MConversion of Exercise of derivative security at price 3.13 per share.D2022-03-01Director40k
HALEY PATRICK JOSEPHSale at price 19.53 per share.D2022-02-25Officer31.24k
HESSEKIEL JEFFREY JSale at price 20.00 per share.D2022-02-24General Counsel18k
PAPADOPOULOS STELIOS BSale at price 19.56 per share.D2022-02-22Director84.52k
FELDBAUM CARL B. ESQSale at price 19.49 per share.D2022-02-22Director20k
FELDBAUM CARL B. ESQConversion of Exercise of derivative security at price 3.13 per share.D2022-02-22Director20k
HALEY PATRICK JOSEPHSale at price 17.91 per share.D2022-02-03Officer60k
HALEY PATRICK JOSEPHConversion of Exercise of derivative security at price 1.90 per share.D2022-02-03Officer60k
GOODMAN VICKI LStock Award(Grant) at price 0.00 per share.D2022-01-04Officer250k
MORRISSEY MICHAEL MStock Gift at price 0.00 per share.D2021-12-23Chief Executive Officer11k
WRIGHT JACQUELINEStock Award(Grant) at price 0.00 per share.D2021-12-16Director20.86k
MORRISSEY MICHAEL MStock Award(Grant) at price 0.00 per share.D2021-12-15Chief Executive Officer46.48k
LAMB PETERStock Award(Grant) at price 0.00 per share.D2021-12-15Officer18.74k
LAMB PETERSale at price 17.44 per share.D2021-12-15Officer47.5k
LAMB PETERConversion of Exercise of derivative security at price 6.21 per share.D2021-12-15Officer47.5k
HESSEKIEL JEFFREY JStock Award(Grant) at price 0.00 per share.D2021-12-15General Counsel9.99k
SENNER CHRISTOPHER J.Stock Award(Grant) at price 0.00 per share.D2021-12-15Chief Financial Officer19.49k
HALEY PATRICK JOSEPHStock Award(Grant) at price 0.00 per share.D2021-12-15Officer8.99k
MORRISSEY MICHAEL MStock Gift at price 0.00 per share.D2021-11-29Chief Executive Officer196.52k
HALEY PATRICK JOSEPHSale at price 17.25 per share.D2021-11-24Officer17.24k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Exelixis Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Exelixis Inc

Here is the result of two systematic investment strategies applied to Exelixis Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Exelixis Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Exelixis Inc:

Exelixis Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -8.37% on the backtest period.

Performance at glance

Performance

-8.37 %

Latent gain

-144.99 $

Invested capital

1732.51 $

Annualized return

-2.04 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Exelixis Inc

This is the result of two momentum investment strategies applied to Exelixis Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Exelixis Inc

The following chart shows all the entries opened by the momentum investment system on Exelixis Inc:

Exelixis Inc momentum entries
  • The first momentum investment strategy would give -1.44% of return on Exelixis Inc. That represents -72.16$ of latent gain with 5028.32$ of employed capital.
  • The second momentum investment strategy would give -2.33% of return on Exelixis Inc. That represents -87.66$ of latent gain with 3766.06$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-1.44 %

Latent gain

-72.16 $

Invested capital

5028.32 $

Annualized return

-0.08 %
Performance at glance (2Q Momentum)

Performance

-2.33 %

Latent gain

-87.66 $

Invested capital

3766.06 $

Annualized return

-0.64 %

Momentum equity curve on Exelixis Inc

The following chart shows the equity curve of the two momentum strategies applied to Exelixis Inc:

Exelixis Inc momentum equity

Note: the dividends potentially given by Exelixis Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Exelixis Inc

The following chart shows the employed capital evolution of the two momentum strategies on Exelixis Inc since the beginning:

Exelixis Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Exelixis Inc

Buy the dip entry openings on Exelixis Inc

Exelixis Inc

The performance achieved by the robo-advisor on Exelixis Inc is -0.17%. That represents -2.14$ of latent gain with 1241.18$ of employed capital. The following chart shows Exelixis Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Exelixis Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-0.17 %

Latent gain

-2.14 $

Invested capital

1241.18 $

Annualized return

-0.08 %

Equity curve of the strategy applied to Exelixis Inc

The following chart shows the result of the investment strategy applied to Exelixis Inc:

Exelixis Inc

Note: the dividends potentially given by Exelixis Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Exelixis Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Exelixis Inc:

Exelixis Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Exelixis Inc

In this section, I will compare the three previous investment strategies applied to Exelixis Inc.

Equity curve comparison on Exelixis Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Exelixis Inc investment strategy comparison

Employed capital comparison on Exelixis Inc

Exelixis Inc investment comparison

Performance comparison on Exelixis Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -8.37% -144.99$ 1732.51$ -2.04%
Momentum 1 quarter -1.44% -72.16$ 5028.32$ -0.37%
Momentum 2 quarters -2.33% -87.66$ 3766.06$ -0.64%
Non-directional -0.17% -2.14$ 1241.18$ -0.08%
Annualized return comparison

Automatic investment

-2.04 %

Momentum 1Q

-0.64 %

Momentum 2Q

-0.64 %

Non-directional

-0.08 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Exelixis Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • LUKS GROUP (VN)

  • Note: The algorithm computes the probability of correlation between Exelixis Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Exelixis Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Exelixis Inc
    Country United States
    City Alameda
    Address 1851 Harbor Bay Parkway
    Phone 650 837 7000
    Website www.exelixis.com
    FullTime employees 954
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker EXEL
    Market www.nasdaq.com

    Exelixis Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown